Cargando…

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma

Lenvatinib is a multitarget tyrosine kinase inhibitor (TKI) approved for the treatment of several types of cancers, including metastatic differentiated thyroid cancer (DTC). The intended targets include VEGFR 1–3, FGFR 1–4, PDGFRα, RET, and KIT signaling pathways, but drug resistance inevitably deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Chunying, Rabold, Katrin, Netea, Mihai G., Jaeger, Martin, Netea-Maier, Romana T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960916/ https://www.ncbi.nlm.nih.gov/pubmed/36839733 http://dx.doi.org/10.3390/pharmaceutics15020412

Ejemplares similares

Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinoma
por: Rabold, Katrin, et al.
Publicado: (2022)

Metabolic programming of tumor associated macrophages in the context of cancer treatment
por: Crezee, Thomas, et al.
Publicado: (2020)

Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers
por: Peng, Chunying, et al.
Publicado: (2021)

Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages
por: Arts, Rob J. W., et al.
Publicado: (2016)

Role of Genetic Variants of Autophagy Genes in Susceptibility for Non-Medullary Thyroid Cancer and Patients Outcome
por: Plantinga, Theo S., et al.
Publicado: (2014)

Concomitant systemic inflammation and cellular immunosuppression in patients with Cushing's syndrome
por: van Houten, Pepijn, et al.
Publicado: (2023)

IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer
por: Crezee, Thomas, et al.
Publicado: (2021)

Enhanced lipid biosynthesis in human tumor-induced macrophages contributes to their protumoral characteristics
por: Rabold, Katrin, et al.
Publicado: (2020)

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice
por: Capdevila, Jaume, et al.
Publicado: (2023)

The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis
por: Bojoga, Andreea, et al.
Publicado: (2020)

A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer
por: Fleming, Kathryn, et al.
Publicado: (2018)

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer
por: Plantinga, Theo S., et al.
Publicado: (2016)

Autophagy in Thyroid Cancer: Present Knowledge and Future Perspectives
por: Netea-Maier, Romana T., et al.
Publicado: (2015)

The impact of pre-existing thyroid diseases on susceptibility to respiratory infections or self-reported sickness during the SARS-CoV-2 pandemic
por: Rops, Maartje A. J., et al.
Publicado: (2022)

Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non‐medullary thyroid cancer
por: Crezee, Thomas, et al.
Publicado: (2021)

An Explorative Study on Monocyte Reprogramming in the Context of Periodontitis In Vitro and In Vivo
por: Noz, Marlies P., et al.
Publicado: (2021)

Abnormal Thyroid Function Is Associated With Lymphopenia in Bacterial Sepsis and COVID-19
por: Grondman, Inge, et al.
Publicado: (2021)

Akt1 genetic variants confer increased susceptibility to thyroid cancer
por: Crezee, Thomas, et al.
Publicado: (2020)

Needs, Preferences, and Values during Different Treatment Decisions of Patients with Differentiated Thyroid Cancer
por: Koot, Anna, et al.
Publicado: (2021)

Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing
por: Koot, Anna, et al.
Publicado: (2023)

Modulation of inflammation by autophagy: Consequences for human disease
por: Netea-Maier, Romana T., et al.
Publicado: (2015)

Thyroid Microcarcinoma in Pediatric Population in Romania
por: Stefan, Andreea-Ioana, et al.
Publicado: (2021)

Acromegaly, inflammation and cardiovascular disease: a review
por: Wolters, Thalijn L. C., et al.
Publicado: (2020)

Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis
por: Negura, Ion, et al.
Publicado: (2023)

The Influence of Energy Depletion by Metformin or Hypocaloric Diet on Thyroid Iodine Uptake in Healthy Volunteers: a Randomized Trial
por: Sloot, Yvette J. E., et al.
Publicado: (2019)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib
por: Jin, Meihua, et al.
Publicado: (2023)

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation()()()
por: Eissing, Marc, et al.
Publicado: (2018)

Thyroid: Medullary Carcinoma
por: Somnay, Yash R., et al.
Publicado: (2013)

Clinical Characteristics, Diagnostic Approach and Outcome of Thyroid Incidental Findings vs. Clinically Overt Thyroid Nodules: An Observational Single-Centre Study
por: Jansen, Tom, et al.
Publicado: (2023)

IGF-I Influences Everolimus Activity in Medullary Thyroid Carcinoma
por: Gentilin, Erica, et al.
Publicado: (2015)

Medullary carcinoma of the thyroid gland.
por: Russell, C.
Publicado: (1980)

Diagnosis of medullary thyroid cancer
por: Marchisotta, Stefania, et al.
Publicado: (2009)

Medullary carcinoma of the thyroid: an update
por: Alevizaki, Maria
Publicado: (2013)

Pediatric Medullary Thyroid Carcinoma
por: Starenki, Dmytro, et al.
Publicado: (2015)

Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease
por: Noz, Marlies P, et al.
Publicado: (2020)

Toward Identification of the Genetic Risk Profile for Cryptococcal Disease in HIV-Infected Patients
por: Netea, Mihai G.
Publicado: (2013)

Prolonged duration of response in lenvatinib responders with thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2018)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Efficacy of lenvatinib in a patient with anaplastic thyroid cancer
por: Oishi, Kazuyuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s8f3v199ocoi8qg1pnueru49td